Search Results

You are looking at 231 - 240 of 576 items for :

  • Refine by Access: All x
Clear All
Full access

Therapeutically Induced Changes in HER2, HER3, and EGFR Protein Expression for Treatment Guidance

Shankar Sellappan, Adele Blackler, Wei-Li Liao, Emily O'Day, Peng Xu, Sheeno Thyparambil, Fabiola Cecchi, Todd Hembrough, and Daniel V.T. Catenacci

in the expression of HER3 protein, treatment was amended to trastuzumab plus pertuzumab with a FOLFOX-chemotherapy backbone. The patient demonstrated some clinical improvement with dysphagia, anorexia, and fatigue, but objectively showed progressive

Full access

Myeloproliferative Neoplasms, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology

Ruben Mesa, Catriona Jamieson, Ravi Bhatia, Michael W. Deininger, Aaron T. Gerds, Ivana Gojo, Jason Gotlib, Krishna Gundabolu, Gabriela Hobbs, Rebecca B. Klisovic, Patricia Kropf, Sanjay R. Mohan, Stephen Oh, Eric Padron, Nikolai Podoltsev, Daniel A. Pollyea, Raajit Rampal, Lindsay A. M. Rein, Bart Scott, David S. Snyder, Brady L. Stein, Srdan Verstovsek, Martha Wadleigh, Eunice S. Wang, Mary Anne Bergman, Kristina M. Gregory, and Hema Sundar

poor response to therapy and short survival. 2 – 4 The symptom profile varies within and between each MPN subtype but often includes constitutional symptoms, fatigue, pruritus, weight loss, symptoms from splenomegaly, and variable lab abnormalities

Full access

Intermittent Versus Continuous Androgen Deprivation Therapy

Celestia S. Higano

) and seriously impact the quality of life of both the patient and, indirectly, his partner (eg, fatigue, hot flashes, decreased libido, loss of masculine physical characteristics, depression). These side effects have been significant enough to explore

Full access

Full Spectrum: Efficacy and Toxicity of Immunotherapy in Metastatic Melanoma

Matthew Zibelman and Anthony J. Olszanski

, dysphagia, or dyspnea. He reported no significant weight loss, fevers, or chills, and had not noticed any other masses or unusual skin lesions. He did report mild fatigue. A brief trial of antibiotics was prescribed by a primary care physician but did not

Full access

The International Endorsement of US Distress Screening and Psychosocial Guidelines in Oncology: A Model for Dissemination

Mark Lazenby

clinically significant distress. 4 This distress may arise from the disease itself, 5 but also from physical symptoms such as pain and fatigue, 6 from emotional states such as depression and anxiety, and from spiritual concerns. 7 Unaddressed, distress

Full access

An Unusual Presentation of Chronic Myelogenous Leukemia: A Review of Isolated Central Nervous System Relapse

Scott M. Lindhorst, Richard D. Lopez, and Ronald D. Sanders

woman presented with several weeks of progressive fatigue, bruising, and eventually the development of fevers. She had no prior medical problems and took no medications. Physical examination revealed only moderate splenomegaly, measuring 14 cm. On

Full access

Prolonged Response to Anti–PD-1 Antibody Therapy in Chemotherapy-Refractory Cholangiocarcinoma With High Tumor Mutational Burden

Olumide Gbolahan, Neda Hashemi-Sadraei, and Bert O’Neil

radiologic progression. He reported mild abdominal pain and fatigue, but his ECOG performance status was 1, with minimal adverse effects from the previous chemotherapy. The right hepatectomy tumor specimen was sent for panel-based tumor genomic profiling on

Full access

Early Implementation of Palliative Care Can Improve Patient Outcomes

Paul A. Glare

, and spiritual consequences of the disease and its treatment. 4 - 8 In particular, pain, depression, and fatigue are among the most frequent and devastating symptoms, and they can have a considerable impact on a patient’s quality of life. 6 - 12

Full access

Neoadjuvant Immunotherapy–Based Systemic Treatment in MMR-Deficient or MSI-High Rectal Cancer: Case Series

Rahel Demisse, Neha Damle, Edward Kim, Jun Gong, Marwan Fakih, Cathy Eng, Leslie Oesterich, Madison McKenny, Jingran Ji, James Liu, Ryan Louie, Kit Tam, Sepideh Gholami, Wissam Halabi, Arta Monjazeb, Farshid Dayyani, and May Cho

, compatible with tumor regression grade 1. The patient continued to have partial response on subsequent imaging, and tolerated, in total, 11 cycles of pembrolizumab. However, he developed grade 2 fatigue attributed to immunotherapy, which led to therapy

Full access

NCCN Policy Summit: Defining, Measuring, and Applying Quality in an Evolving Health Policy Landscape and the Implications for Cancer Care

Lindsey A.M. Bandini, Leigh Gallo, Terrell Johnson, Kara Martin, Alyssa A. Schatz, Kerin Adelson, Bryan A. Loy, Ronald S. Walters, Tracy Wong, and Robert W. Carlson

care issues, which the panelists offered as an opportunity for enhancement of the OCM. 10 With an increase in data collection, panelists also warned of survey fatigue, or physician and patient burnout resulting from extensive surveying. Relying on sick